logo

For the Inventor, By the Inventor

Berlin, Germany

Mologen Ag


USPTO Granted Patents = 15

% Expired Patents = 53.3



Trademarks = 1

Forward Citations = 68

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal Burghardt Wittig (10 out of 13 patents)

silverMedal Manuel Schmidt (9 out of 11 patents)

bronzeMedal Matthias Schroff (8 out of 12 patents)

4.  Kerstin Kapp (4 out of 6 patents)

5.  Alfredo Zurlo (2 out of 4 patents)

6.  Tomislav Dobric (2 out of 2 patents)

7.  Detlef Oswald (2 out of 2 patents)

8.  Laura Fuertes-López (2 out of 2 patents)

9.  Marcos Timón-Jiménez (2 out of 2 patents)

10.  Christiane Juhls (2 out of 2 patents)

11.  Claas Junghans (2 out of 6 patents)

12.  Christiane Kleuss (1 out of 1 patent)

13.  Janine Loehr (1 out of 1 patent)

14.  Dennis Kobelt (1 out of 1 patent)

15.  Heribert Bohlen (1 out of 3 patents)


15 patents:

1. 10604760 - Combination comprising immunostimulatory oligonucleotides (2020-03-31),
2. 10487333 - Combination comprising immunostimulatory oligonucleotides (2019-11-26),
3. 10280424 - Covalently closed non-coding immunomodulatory DNA construct (2019-05-07),
4. 10006032 - Predictive biomarker for cancer therapy (2018-06-26),
5. 9499815 - Multimer for immunostimulation (2016-11-22),
6. 9375435 - Use of a DNA expression construct (2016-06-28),
7. 9345754 - Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine (2016-05-24),
8. 9212366 - Immune modulating oligonucleotides in connection with chemotherapeutic measures (2015-12-15),
9. 9012620 - DNA constructs for specific inhibition of gene expression by RNA interference (2015-04-21),
10. 8669100 - [object Object] (2014-03-11),
11. 8017591 - Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals (2011-09-13),
12. 7915035 - Vaccine against oncovirus infections such as infections by feline leukosis virus of the cat (2011-03-29),
13. 7795406 - Agent for treating leishmania infections (2010-09-14),
14. 7635468 - Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine (2009-12-22),
15. 7074772 - Design principle for the construction of expression constructs for gene therapy (2006-07-11),
Mologen AG is a biotechnology company based in Berlin, Germany, specializing in the development of innovative immunotherapies for the treatment of cancer and infectious diseases. The company focuses on harnessing the power of the immune system to create therapeutic solutions that can enhance patient outcomes. Mologen's research is centered around proprietary technologies that aim to stimulate immune responses, positioning it at the forefront of the biopharmaceutical industry in the realm of targeted therapies.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

15 Patents

#67 in D-1000 Berlin

#2,772 in Germany

#39,881 in the World

Berlin, DE
Berlin, Germany

Mologen Ag

Forward Citations = 68

20 inventors:

goldMedal Burghardt Wittig (10 out of 13 patents)

silverMedal Manuel Schmidt (9 out of 11 patents)

bronzeMedal Matthias Schroff (8 out of 12 patents)

4.  Kerstin Kapp (4 out of 6 patents)

5.  Alfredo Zurlo (2 out of 4 patents)

Please report any incorrect information to [email protected]
Loading…